PI3K/AKT/mTOR

Open Access
CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway
Chao Xu, Zekun Li, Yueying Shan, Chunhua She, Yanfang Yang, Tianxing Zhou, Yongjie Xie, Bo Ni, Chenyang Meng, Guangcong Shen, Boyang Fu, Guannan Sheng, Liangliang Wu, Jinlong Pei, Tiansuo Zhao, Song Gao, Hongwei Wang, Chengqi Deng, Kaiyuan Wang, Antao Chang, Chongbiao Huang, Lei Shi, Shengyu Yang, Jun Yu, Jihui Hao and Xiuchao Wang

Cancer Biology & Medicine December 2025, 22 (12) 1558-1577; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0058
You have access
Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway
Yehui Shi, Wenwen Zhang, Yingnan Ye, Yanan Cheng, Lei Han, Pengpeng Liu, Weipeng Zhao, Zhongsheng Tong and Jinpu Yu

Cancer Biology & Medicine August 2018, 15 (3) 314-321; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0188

Main menu